Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic reviewEdward Bataillard, Tarec Christoffer El‐Galaly, Toby A. Eyre et al.|Blood Advances|2021Cited by 61
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Jason T. Romancik et al.|Blood|2023Cited by 47
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Paolo Strati, Allison Rosenthal et al.|Blood Advances|2022Cited by 37
Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell LymphomaDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 1
A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell TherapySushanth Gouni, Paolo Strati, Allison Rosenthal et al.|Blood|2021Cited by 1